Quantitative Systematic Strategies LLC bought a new position in shares of Elizabeth Arden Inc. (NASDAQ:RDEN) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,863 shares of the company’s stock, valued at approximately $176,000.
Other hedge funds have also recently made changes to their positions in the company. Royce & Associates LP raised its stake in shares of Elizabeth Arden by 7.7% in the first quarter. Royce & Associates LP now owns 1,240,894 shares of the company’s stock worth $10,163,000 after buying an additional 89,102 shares during the last quarter. Spark Investment Management LLC purchased a new stake in shares of Elizabeth Arden during the first quarter worth about $217,000. Geode Capital Management LLC raised its stake in shares of Elizabeth Arden by 2.9% in the first quarter. Geode Capital Management LLC now owns 172,530 shares of the company’s stock worth $1,413,000 after buying an additional 4,897 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new stake in shares of Elizabeth Arden during the first quarter worth about $211,000. Finally, Sphinx Trading LP purchased a new stake in shares of Elizabeth Arden during the second quarter worth about $110,000. 70.70% of the stock is currently owned by institutional investors.
Elizabeth Arden Inc. (NASDAQ:RDEN) remained flat at $13.98 during mid-day trading on Tuesday. Elizabeth Arden Inc. has a one year low of $5.02 and a one year high of $14.14. The company’s 50-day moving average is $13.93 and its 200-day moving average is $10.50.
Elizabeth Arden (NASDAQ:RDEN) last announced its earnings results on Wednesday, August 10th. The company reported ($0.58) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.20. Elizabeth Arden had a negative net margin of 7.43% and a negative return on equity of 38.72%. The firm had revenue of $192.70 million for the quarter, compared to analyst estimates of $193.75 million. On average, equities research analysts forecast that Elizabeth Arden Inc. will post ($0.49) EPS for the current fiscal year.
A number of research firms have recently weighed in on RDEN. B. Riley reaffirmed a “neutral” rating and set a $14.00 price objective on shares of Elizabeth Arden in a research report on Wednesday, June 22nd. Zacks Investment Research raised Elizabeth Arden from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Wednesday, July 6th.
About Elizabeth Arden
Elizabeth Arden, Inc is a global beauty products company with a portfolio of fragrance, skin care and cosmetics brands. The Company’s product portfolio includes Elizabeth Arden Brand, such as the Elizabeth Arden skin care brands (Visible Difference, Ceramide, Prevage, Eight Hour Cream, Superstart and Elizabeth Arden Pro), Elizabeth Arden branded lipstick, foundation and other color cosmetics products and Elizabeth Arden fragrances (Red Door, 5th Avenue, Elizabeth Arden Green Tea and UNTOLD); designer fragrances, which include Juicy Couture, John Varvatos, and Wildfox Couture; Heritage Fragrances, such as Curve, Elizabeth Taylor, Britney Spears, Halston, Ed Hardy, Geoffrey Beene, Alfred Sung, Giorgio Beverly Hills, Lucky, PS Fine Cologne, White Shoulders, BCBGMAXAZRIA, Rocawear and Jennifer Aniston, and celebrity fragrances, which include the fragrance brands of Justin Bieber, Mariah Carey, Nicki Minaj and Taylor Swift.
Want to see what other hedge funds are holding RDEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elizabeth Arden Inc. (NASDAQ:RDEN).
Receive News & Ratings for Elizabeth Arden Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elizabeth Arden Inc. and related companies with MarketBeat.com's FREE daily email newsletter.